Qynapse offers groundbreaking peace of mind by providing results you can trust.

Our Story

For healthcare providers, payers, pharma and, above all, patients and their loved ones, Qynapse brings groundbreaking peace of mind to the global fight against CNS disease. Founded in Paris, France in 2015, as a spin-off from the CATI consortium of neuroimaging research laboratories, Qynapse is on a mission to advance the accuracy and reliability of CNS disease screening and monitoring in both clinical routine settings and in clinical trial applications.

Our FDA-Cleared and CE-Marked neuroimaging software platform, QyScore®, produces a wide range of automated measures of neuroinflammation and neurodegeneration to support more accurate diagnosis in clinical care and imaging endpoints in a clinical trial setting. In clinical routine, QyScore® has the potential to support timely diagnosis, disease & therapy monitoring, tailored treatment plans and facilitate therapeutic switching. In a clinical trial setting, QyScore® has the potential to reduce reading variability in images, the potential to improve pre-identification of patients eligible for CNS trials, automates image pre-processing, quality control and image analysis, and the potential for better measurement of drug efficacy and safety.

Our predictive research use only platform QyPredict®, powered by machine learning algorithms is being developed to increase the possibility to predict a patient’s individual disease trajectory, which would transform and improve timely intervention and treatment plans, and drastically improve quality of life and outcomes.

Meet Our Team

Olivier Courrèges

Founder & CEO

Serge Barbe

Chief Product and Technology Officer

Adam J. Schwarz, PhD

Chief Scientific Officer

Scott Keddy, MBA

VP Business Development

Nicolas Guizard, PhD

R&D LEADER, DATA SCIENCE

Mathias Breuil

QUALITY & REGULATORY AFFAIRS DIRECTOR

Join us.

Apply today.

 

Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa (CE BSI). 

Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.

Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.

 

Scott Keddy, MBA

VP BUSINESS DEVELOPMENT

Scott joined Qynapse in 2021 bringing 20 years of experience spanning the global pharmaceutical industry. He has worked with various pharmaceutical, biotechs and non-profits across therapeutic treatment areas including Alzheimer’s disease and other central nervous system (CNS) disorders. Scott has worked with several start-ups contributing to their operations and rapid revenue generation.

Prior to Qynapse, Scott served in a key commercial role for Cytel where he achieved significant entry and growth within Japanese pharmaceutical and biotech companies. His career in the clinical space has included working with software, full service CROs and central laboratories in business development roles after starting in the industry in operations. 

Scott holds a Master’s in Business Administration from McMaster University and has an undergraduate degree in Mathematics from Western University as well as having studied at University of Ottawa and BI Norwegian Business School.

 

Nicolas Guizard, PhD

R&D Leader, Data Science

Nicolas joined Qynapse in 2021 as Data Science Leader. To Qynapse, he brings 15 years of experience in image processing for medical device applications and clinical studies in the United States, Canada and France.

Prior to Qynapse, Nicolas worked as the team leader in industry at Imagia, Canada, on machine learning algorithms to develop real-time endoscopy solutions.

Nicolas earned his PhD in biomedical engineering from McGill University, Canada, with a focus on longitudinal brain MRI morphometry analyses for neurodegenerative diseases.

 

 

Olivier Courrèges

FOUNDER & CEO

Like most of us, Olivier Courrèges has felt the toll that an ambiguous CNS prognosis can have on a family. After his grandparents both experienced the onset of unique central nervous system disorders, Olivier dedicated all of his expertise in healthcare and tech toward improving the clarity of CNS disease screening.

After time in the United States where he served as the Director of Strategy and Development for Merck Millipore in a life sciences division, Olivier returned to his home in France with these questions and joined forces with the clinicians of the CATI consortium in Paris, an academic service platform supporting more than 30 multicenter neuroimaging studies in the fields of neurodegenerative diseases and psychiatry.

Together, with several other clinicians and researchers on the forefront of neuroscience, Olivier founded Qynapse in 2015. He’s remained steadfast in the company’s mission from day one serving as CEO.

Earlier on in his career, he co-founded Open Pricer, a company that delivered pricing software to several Fortune 500 companies. Olivier holds a master’s in business administration from Toulouse Business School and a master’s in technology management from Ecole Centrale Paris.

 

Serge Barbe

Chief Product and Technology Officer

Serge joined Qynapse in 2021 as Chief Product & Technology Officer bringing over 15 years as Project leader, VP engineer and Chief Technical officer in the digital technologies industry. He also served for more than 10 years as Business line manager in digital environment, dealing with strategy, product marketing, partnership, development of SaaS, service delivery and service operations. 

Serge achieved significant milestones throughout his career, such as the development and operation of ApplePay Cloud system that enrolled hundreds of banks to the mobile digital payment wallet in a stringent context of availability, performance, cyber security, privacy, and compliancy with international and national standards.

He also managed large and critical contracts execution on a worldwide basis, as well as the international growth of technical teams based in US, Canada, Brazil, China, Singapore, Western and Eastern Europe.

Serge holds an Engineer Degree from INSA, Lyon and a Master’s in Business Administration from INSEAD.

 

Adam J. Schwarz, PhD

CHIEF SCIENTIFIC OFFICER

Adam J. Schwarz, Ph.D., joined Qynapse in 2021 as Chief Scientific Officer. He brings over 20 years of experience in the global pharmaceutical industry with a focus on translational and clinical imaging, both MRI and PET, across a range of psychiatric and neurologic disorders.

Prior to Qynapse, Dr. Schwarz served in key scientific leadership roles, heading the clinical imaging group at Takeda Pharmaceuticals and occupying several roles including Head of Imaging over more than a decade at Eli Lilly and Company. Before that, he worked as a neuroimaging scientist with GlaxoSmithKline in Verona, Italy, and as a software engineer on MRI scanner development with Marconi Medical Systems in Farnham, UK.

Throughout his career, he has developed and maintained strong relationships with academic groups, specialist companies and consortia to further the science and application of imaging as a tool to better understand disease mechanisms and enhance drug development. Dr. Schwarz has an active scientific profile and has authored over a hundred peer-reviewed articles, two books and several invited book chapters.

Adam Schwarz holds a B.Sc. with First Class Honours in Physics and a Ph.D. in Electrical and Electronic Engineering, both from the University of Canterbury (New Zealand) and held a postdoctoral position as an imaging physicist at the Institute of Cancer Research / Royal Marsden Hospital in London, UK.

 

Mathias Breuil

Quality & Regulatory Affairs Director

Mathias joined Qynapse in 2021 as Quality & Regulatory Affairs Director. He brings over 15 years of experience in the healthcare industry in assurance quality and regulations of medical devices for the international market including the conduct of multiple registration projects worldwide.

Prior to Qynapse, Mathias served as Regulatory Affairs Manager at EOS imaging group which manufactures, and markets internationally X-ray acquisition systems and dedicated diagnostic imaging software. Before that, he worked as a Regulatory Affairs Specialist at Stago an IVD medical device company specializing in hemostasis.

Through his experiences, Mathias gained a strong knowledge of international regulations and standards applying to medical devices and achieved to get product marketing authorizations in many areas such as Europe, USA, Canada, Australia, Japan, China, middle east and LATAM.

Mathias holds a Master’s degree in Physico-Chemistry from the university of Paris-Saclay.